Jetema has secured product approval from the Thai Food and Drug Administration (TFDA) for its botulinum toxin product, establishing a bridgehead for entry into the Southeast Asian aesthetic market.

According to a regulatory filing on the 2nd, the approved product is 'Jetema The Toxin Injection 100 Units (Clostridium botulinum toxin type A).' This approval covers the indication for the improvement of moderate to severe glabellar lines.

Following the product approval application submitted to the Thai TFDA on December 11, 2025, the product received final approval on June 26, 2026. The company promptly disclosed this upon receiving the official approval letter from its Thai partner on July 2, 2026.

Through this approval, Jetema has laid the groundwork to officially enter key Southeast Asian aesthetic markets, including Thailand. In particular, the company plans to use this as a stepping stone to continuously expand its track record of multinational product approvals globally.

Furthermore, the company intends to actively leverage the content of this disclosure in future press releases and IR (Investor Relations) materials to enhance corporate value.